MX2016005287A - Metodos para el tratamiento de distrofias musculares. - Google Patents
Metodos para el tratamiento de distrofias musculares.Info
- Publication number
- MX2016005287A MX2016005287A MX2016005287A MX2016005287A MX2016005287A MX 2016005287 A MX2016005287 A MX 2016005287A MX 2016005287 A MX2016005287 A MX 2016005287A MX 2016005287 A MX2016005287 A MX 2016005287A MX 2016005287 A MX2016005287 A MX 2016005287A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- methods
- muscular dystrophies
- composition
- dystrophy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Nutrition Science (AREA)
- Rheumatology (AREA)
- Physiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención se relaciona con, inter alia, el tratamiento de distrofia muscular (por ejemplo, Distrofia Muscular de Duchenne), por ejemplo, utilizando una composición, por ejemplo, una composición que comprende el Compuesto (I), o una sal farmacéuticainente aceptable, profármaco o metabolito del mismo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361895832P | 2013-10-25 | 2013-10-25 | |
PCT/US2014/062178 WO2015061685A1 (en) | 2013-10-25 | 2014-10-24 | Methods for treatment of muscular dystrophies |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2016005287A true MX2016005287A (es) | 2017-02-22 |
Family
ID=52993619
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016005287A MX2016005287A (es) | 2013-10-25 | 2014-10-24 | Metodos para el tratamiento de distrofias musculares. |
Country Status (9)
Country | Link |
---|---|
US (2) | US20160250188A1 (es) |
EP (1) | EP3060206A4 (es) |
JP (1) | JP2016538269A (es) |
CN (1) | CN105979943A (es) |
AU (1) | AU2014339917A1 (es) |
BR (1) | BR112016009214A8 (es) |
CA (1) | CA2928235A1 (es) |
MX (1) | MX2016005287A (es) |
WO (1) | WO2015061685A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2643856B1 (es) | 2016-05-24 | 2018-08-03 | Universidad Del Pais Vasco / Euskal Herriko Unibertsitatea | Triazoles para la regulación de la homeostasis de calcio intracelular |
EP4066850A3 (en) * | 2017-02-22 | 2022-11-23 | Bioincept LLC | Peptides and methods of treating dystrophy-related disorders using the same |
US20210361635A1 (en) * | 2018-06-05 | 2021-11-25 | The Regents Of The University Of California | Methods for treating muscular dystrophies |
CN113924085A (zh) * | 2019-04-12 | 2022-01-11 | 加利福尼亚大学董事会 | 用于增加肌肉量和氧化代谢的组合物和方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0715087D0 (en) * | 2007-08-03 | 2007-09-12 | Summit Corp Plc | Drug combinations for the treatment of duchenne muscular dystrophy |
GB2463514C (en) * | 2008-09-11 | 2018-09-26 | Galapagos Nv | Imidazolidine compounds and uses therefor |
ITBO20090078A1 (it) * | 2009-02-13 | 2010-08-14 | Consiglio Nazionale Ricerche | Composti per il trattamento del tumore alla prostata e procedimenti per la loro sintesi |
-
2014
- 2014-10-24 WO PCT/US2014/062178 patent/WO2015061685A1/en active Application Filing
- 2014-10-24 EP EP14856707.6A patent/EP3060206A4/en not_active Ceased
- 2014-10-24 CA CA2928235A patent/CA2928235A1/en not_active Abandoned
- 2014-10-24 JP JP2016526156A patent/JP2016538269A/ja active Pending
- 2014-10-24 US US15/031,139 patent/US20160250188A1/en not_active Abandoned
- 2014-10-24 MX MX2016005287A patent/MX2016005287A/es unknown
- 2014-10-24 AU AU2014339917A patent/AU2014339917A1/en not_active Abandoned
- 2014-10-24 CN CN201480070003.0A patent/CN105979943A/zh active Pending
- 2014-10-24 BR BR112016009214A patent/BR112016009214A8/pt not_active Application Discontinuation
-
2018
- 2018-10-24 US US16/169,019 patent/US20190167640A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2014339917A1 (en) | 2016-05-12 |
EP3060206A1 (en) | 2016-08-31 |
JP2016538269A (ja) | 2016-12-08 |
WO2015061685A1 (en) | 2015-04-30 |
BR112016009214A8 (pt) | 2020-03-24 |
EP3060206A4 (en) | 2017-04-19 |
US20190167640A1 (en) | 2019-06-06 |
CA2928235A1 (en) | 2015-04-30 |
CN105979943A (zh) | 2016-09-28 |
US20160250188A1 (en) | 2016-09-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12019501321A1 (en) | Methods of treating or preventing cholesterol related disorders | |
PH12015502031A1 (en) | Tetrahydropyrrolothiazine compounds | |
PH12016500169A1 (en) | Polymorph of syk inhibitors | |
UA117976C2 (uk) | Сполуки амінопіримідинілу як інгібітори jak | |
MX2015011913A (es) | Moduladores de acido oxabiciclo[2.2.2] gpr120. | |
MX2015005858A (es) | Moduladores del receptor acoplado a proteina g (gpr40) de dihidropirazol. | |
MX2016006336A (es) | Compuestos pirazolopirimidina. | |
MX361499B (es) | Baricitinib deuterado. | |
MX2015005735A (es) | Moduladores de dihidropirazol de receptor acoplado a la proteona g (gpr40). | |
MY197698A (en) | Oxysterols and methods of use thereof | |
MX2015005720A (es) | Moduladores de dihidropirazol de receptor acoplado a la proteina g (gpr40). | |
IN2015DN00598A (es) | ||
NZ729037A (en) | Carboxylic acid compound, method for preparation thereof, and use thereof | |
MY187718A (en) | Pharmaceutical formulations | |
MX366820B (es) | Moduladores de gpr120 del acido biciclo[2.2.2]. | |
EA201490756A1 (ru) | Разагилина цитрамид | |
MX2020003020A (es) | Compuestos de aminocarbonilcarbamato. | |
EA201592268A1 (ru) | Дигидропиридиноновые ингибиторы mgat2 | |
MY162886A (en) | Novel tetrahydropyridopyrimidine compound or salt thereof | |
MX362879B (es) | Usos novedosos. | |
PH12018500903A1 (en) | Pyranodipyridine compound | |
IN2014DN07996A (es) | ||
MX362919B (es) | Moduladores del receptor acoplado a proteína-g 120 (gpr120) de ácido biciclo-[2.2.1]. | |
JOP20200030A1 (ar) | مركب خماسي الحلقة | |
MX2016005287A (es) | Metodos para el tratamiento de distrofias musculares. |